报价延迟最少15分钟:2025/09/05 22:10 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.303 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-37.38/-13.90
|
|
企业价值
5.10M
|
| 资产负债 |
|
每股账面净值
-1.51
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/05 22:10 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models. |
